Found 365 Neoplasms trials
A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
The research study is being conducted to develop a test to predict a common complication after lung transplant called primary graft dysfunction (PGD). Predicting PGD before using donor organs may help reduce deaths and improve outcomes of patients receiving a lung transplant in the future.
In this study, subjects diagnosed with liver cancer undergo the HepQuant SHUNT diagnostic assay as a means to determine liver function. The results of this assay will potentially inform radiation treatment.
The primary purpose of this study is to gain information about the safety and activity of grapiprant when taken with pembrolizumab in patients who have actively growing or spreading type of advanced stage lung cancer called non-small cell lung cancer (NSCLC).
The purpose of this study is to see if JNJ-61186372 is safe and useful for treating patients with advanced, metastatic, non-small cell lung cancer (NSCLC).
This phase II/III trial studies the usefulness of treatment with nivolumab and ipilimumab in addition to standard of care chemotherapy and radiation therapy in patients with esophageal and gastroesophageal junction adenocarcinoma who are undergoing surgery. This trial is open to Penn Medicine's Abramson Cancer Center patients only. Please contact the …
Request for collaborative review: WIRB serving as IRB of record.
Non-Hodgkin lymphoma is a potentially curable condition with standard cancer treatment drugs (chemotherapy) and steroids. Standard lymphoma treatment includes chemotherapy, or cancer-fighting drugs, called etoposide, vincristine, cyclophosphamide, prednisone and doxorubicin (called EPOCH).
This double-blind, randomized controlled trial will examine the safety and tolerability of the combination of intravenous administration of VB-111 and paclitaxel compared to placebo and paclitaxel in patients with platinum resistant ovarian cancer.
The primary outcomes will be to establish the safety and feasibility of inhaled imaging in patients with NSCLCand to develop a robust RT planning protocol incorporating both standard of care metrics and those derived from inhaled imaging
